Drug profile · INN
acoramidis hydrochloride
BEYONTTRA
acoramidis hydrochloride (BEYONTTRA) is a transthyretin stabiliser. Associated with BridgeBio Oncology Therapeutics. Route of administration: oral. Current US regulatory status: approved.
Drug details — acoramidis hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 2
- Data quality
- 0.89
Quick answer
acoramidis hydrochloride (BEYONTTRA) is a transthyretin stabiliser. Associated with BridgeBio Oncology Therapeutics. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Transthyretin stabiliser
Primary target: Transthyretin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is acoramidis hydrochloride?
acoramidis hydrochloride (BEYONTTRA) is a transthyretin stabiliser. Associated with BridgeBio Oncology Therapeutics. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for acoramidis hydrochloride?
BEYONTTRA is a marketed brand name for acoramidis hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of acoramidis hydrochloride?
acoramidis hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.